ARTICLE | Clinical News
MCNA regulatory update
July 20, 2015 7:00 AM UTC
Telesta submitted a BLA to FDA for MCNA to treat high-risk non-muscle invasive bladder cancer in patients who have failed first-line treatment with bacillus Calmette-Guerin (BCG) therapy. The company ...